Key Insights

Highlights

Success Rate

87% trial completion (above average)

Published Results

23 trials with published results (14%)

Research Maturity

78 completed trials (49% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

7.5%

12 terminated out of 159 trials

Success Rate

86.7%

+0.1% vs benchmark

Late-Stage Pipeline

26%

41 trials in Phase 3/4

Results Transparency

29%

23 of 78 completed with results

Key Signals

23 with results87% success12 terminated

Data Visualizations

Phase Distribution

99Total
Not Applicable (27)
Early P 1 (2)
P 1 (12)
P 2 (17)
P 3 (6)
P 4 (35)

Trial Status

Completed78
Unknown32
Recruiting20
Terminated12
Not Yet Recruiting8
Withdrawn4

Trial Success Rate

86.7%

Benchmark: 86.6%

Based on 78 completed trials

Clinical Trials (159)

Showing 20 of 20 trials
NCT01568697RecruitingPrimary

Oral Bacteria and Immune System Problems Involved in Gum Disease (Periodontitis)

NCT04843982Phase 4Terminated

Immunoinflammatory Regulation of Esketamine in Septic Patients

NCT04654988Phase 4Active Not Recruiting

Study to Evaluate the Efficacy of Immunosuppression in Myocarditis or Inflammatory Cardiomyopathy.

NCT07680816Recruiting

Metabolic and Functional Study of γδ T Cells in Critically Ill Patients

NCT07204080Phase 2Not Yet Recruiting

(TNX-1500) in Kidney Transplant Recipients

NCT03386539Phase 3Completed

Tacrolimus/Everolimus vs. Tacrolimus/MMF in Pediatric Heart Transplant Recipients Using the MATE Score

NCT05814432Phase 3Recruiting

Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS

NCT05462561Not ApplicableSuspended

Vascularized Composite Bladder Allograft Transplantation

NCT07578558Phase 2Not Yet Recruiting

NAI for Sepsis With Persistent Lymphopenia

NCT02310867Phase 2RecruitingPrimary

Immunomodulation to Optimize Vascularized Composite Allograft Integration for Limb Loss Therapy

NCT06262776Not ApplicableRecruitingPrimary

Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

NCT06354179Phase 4Recruiting

Evaluation of the Benefits of Administering Immunosuppressive Drugs as Single Daily Doses Over the First Year After Liver Transplantation (EASY)

NCT05043870Phase 4Recruiting

Combined Immunosuppression for Pediatric Crohn's Disease

NCT07479511Active Not Recruiting

Adaptation of Lung Transplant Recipients at Extreme Altitude

NCT00619528Not ApplicableCompletedPrimary

HLA-Identical Sibling Renal Transplant Tolerance

NCT06879106Not ApplicableCompleted

Effect of Cognitive Therapy on Immunosuppressive Treatment Compliance and Motivation

NCT05756036Completed

Torque Teno Virus: A Biomarker of Immunosuppression

NCT01086904Phase 2Completed

Safety and Efficacy of an Inactivated and Non Adjuvanted Vaccine Against Influenza A in Renal Transplant Recipients

NCT07206277Not ApplicableRecruitingPrimary

Fibroscan to Guide Post Transplant Immunosuppression Minimization

NCT05616130Recruiting

Pathological Myeloid Activation After Sepsis and Trauma

Scroll to load more

Research Network

Activity Timeline